RC
OKUR

Rangeley Capital’s OnKure Therapeutics OKUR Stock Holding History

Rangeley Capital’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393K Sell
95,000
-50,000
-34% -$154K 0.38% 56
2025
Q4 		$421K Sell
145,000
-10,490
-7% -$31.4K 0.35% 59
2025
Q3 		$428K Buy
155,490
+125,588
+420% +$311K 0.37% 58
2025
Q2 		$71.5K Buy
+29,902
New +$78.4K 0.09% 58

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rangeley Capital's OKUR Position: Q1 2026 in Review

Rangeley Capital reduced its OnKure Therapeutics (OKUR) stake by 34% in Q1 2026, selling an estimated $154K and leaving 95,000 shares worth $393K. The position accounts for 0.38% of the portfolio, ranked #56.

Rangeley Capital first reported a position in OKUR in Q2 2025 and has held it in 4 quarters since. The position peaked at $428K in Q3 2025. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Rangeley Capital held 95,000 shares of OnKure Therapeutics worth $393K as of Q1 2026.
  • Rangeley Capital sold 50,000 OnKure Therapeutics shares in Q1 2026, an estimated $154K.
  • OnKure Therapeutics made up 0.38% of Rangeley Capital's portfolio in Q1 2026, its #56 holding.
  • Rangeley Capital first reported a position in OnKure Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Rangeley Capital's OnKure Therapeutics position peaked at $428K in Q3 2025.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.